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Summary
Background and purpose: Ambulatory blood pressure monitoring (ABPM) provides an accurate
assessment of blood pressure (BP) and shows non-dipper BP pattern in many sleep apnea syn-
drome (SAS) patients with hypertension (HTN); however, little information is available on the
relationship between the severity of SAS and circadian BP changes in SAS patients without HTN.
This study investigated whether SAS patients without HTN would have different BP courses in
the severity of SAS.
Methods and subjects: Seventy-four consecutive outpatients without HTN [systolic BP (BPs) at
clinic <140mmHg and/or diastolic BP (BPd) at clinic <90mmHg], who received no antihyper-
tensives, underwent overnight polysomnography (PSG) and ABPM. The apnea—hypopnea index
(AHI) was calculated from the PSG results; patients were stratiﬁed into the following 4 groups
based on their AHI: non-SAS, mild-, moderate-, or severe-SAS.
Results: The diurnal BPs and BPd showed no differences in the severity of SAS; however, the
sleep BPs, lowest BPs, and pre-awake BPs were signiﬁcantly higher in the severe-SAS group
than the non-SAS group (p = 0.02, p = 0.04, and p = 0.006, respectively). The sleep BPd and pre-
awake BPd were signiﬁcantly higher in the severe-SAS than the non-SAS (p = 0.01 and p = 0.0003,
respectively) and mild-SAS (p = 0.01 and p = 0.008, respectively) groups.
Conclusions: The results of this study suggested that SAS affected nocturnal BP elevation even in
SAS patients without HTN. The diurnal BP showed no difference in the severity of SAS; however,
the severe-SAS group revealed signiﬁcant nocturnal BP elevation.
© 2009 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
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Introduction
Sleep apnea syndrome (SAS) is widely accepted as one of the
risk factors for cardiovascular events, such as atherosclero-
sis and ischemic heart disease [1,2]. The 7th Report of the
Joint National Committee on Prevention, Detection, Eval-
uation and Treatment of High Blood Pressure (JNC 7) has
deﬁned SAS as a treatable cause of secondary hypertension
(HTN) [3]. Hypoxemia plays a crucial role in sympathetic
nerve system activation in SAS patients, which is related
to nocturnal HTN including secondary HTN and non-dipper
blood pressure (BP) pattern, and triggers cardiovascular
events [4]. Our previous studies reported the inﬂuence of
sleep disordered breathing (SDB) on the acute onset time
of dyspnea and chest pain in patients with congestive heart
failure [5] and acute coronary syndrome [6]. Currently, 24-
h ambulatory blood pressure monitoring (ABPM) provides
accurate BP assessment during sleep. Many studies have
investigated HTN in SAS patients; however, no study has
been conducted on SAS patients without HTN to evaluate
the inﬂuence of SAS on circadian BP changes, especially on
nocturnal BP changes. Here, we investigated whether SAS
patients without HTN would have BP elevation during sleep
as the SAS severity increased.
Subjects and methods
This study was conducted on 74 consecutive SAS outpa-
tients (63 males and 11 females) without HTN who presented
to the St. Marianna University School of Medicine Hospital
between April 2006 and August 2008. HTN was deﬁned as
laboratory-measured systolic BP (BPs)≥ 140mmHg and/or
diastolic BP (BPd)≥ 90mmHg and/or the use of antihy-
pertensives. Blood samples were collected at the ﬁrst
examination for the measurements of the serum concen-
trations of total cholesterol, triglyceride (TG), high-density
lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL)
cholesterol, fasting plasma glucose (FPG), the percentage
of glycosylated hemoglobin (HbA1c), and creatinine. Dia-
betes mellitus was deﬁned as FPG≥ 126mg/dl or patients
who were under diabetes mellitus treatment. Hyperlipi-
demia was deﬁned as total cholesterol≥ 220mg/dl and/or
TG≥ 150mg/dl and/or patients who received hypolipidemic
agents. Obese patients were deﬁned as body mass index
(BMI)≥ 30 kg/m2. Patients with respiratory disease, renal
disease, aged <15 years, and those who refused to undergo
ABPM were excluded from this study. Patients treated with
antihypertensives due to cardiac or renal disease were also
excluded.
Polysomnography
SAS was determined based on the results of full polysomnog-
raphy (PSG) using SLEEP WATHCER® (Compumedics, Abbots-
ford VIC, Australia) or Polymate® (Miyuki Giken Co., Ltd.,
Tokyo, Japan). PSG included an electroencephalogram
(EEG), electro-oculogram, chin electromyogram, and elec-
trocardiogram. Four-channel EEG electrodes were attached
to the right and left sides at the top and back of the head.
A nasal cannula was placed at the nostril to measure the
respiratory airﬂow using a disposable airﬂow sensor, and a
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train gauge sensor monitored respiratory movements of the
hest and abdominal walls. Arterial oxygen saturation (SpO2)
as continuously measured using a pulse oxymeter. Tech-
icians analyzed the sleep states according to the manual
7]. Apnea was deﬁned as a continuous cessation of breath-
ng airﬂow for 10 s, or more per hour of sleep; hypopnea
as deﬁned as a reduction in breathing airﬂow of 50% or
ore of a normal breath with a SpO2 desaturation ≥3% or
n EEG arousal response. The apnea—hypopnea index (AHI)
as calculated as the total number of episodes of apnea
nd hypopnea per hour of sleep based on the PSG results.
ow-oxygen exposure was deﬁned as SpO2 < 90% and the rate
f SpO2 < 90%. The 3% oxygen desaturation index (ODI; the
umber of desaturation episodes per hour of sleep) and 4%
DI were calculated. The sleep states were classiﬁed into
on-rapid eye movement (NREM) sleep, rapid eye move-
ent (REM) sleep, or stage W based on the results of EEG,
hin electromyogram, and the presence or absence of rapid
ye movement. Moreover, NREM sleep was classiﬁed into the
ollowing 4 stages: Stage 1, Stage 2, Stage 3, and Stage 4.
micro-arousal was deﬁned as an abrupt shift in EEG fre-
uency (3≤micro-arousal < 15 s), which was not counted as
tage W; the arousal index was used to evaluate patients’
leep states. The percentages of REM (REM %), Stage 1 (Stage
%), Stage 2 (Stage 2%), Stage 3 (Stage 3%) and Stage 4 (Stage
%) in the total sleep time were calculated and evaluated.
atients with AHI ≥5/h were deﬁned as having SAS. The
everity of SAS was classiﬁed as follows according to AHI:
on-SAS (AHI < 5, n = 11), mild (5≤AHI < 15, n = 20), moder-
te (15≤AHI < 30, n = 22), and severe (30≤AHI, n = 21).
P measurement at the clinic
P was measured twice using a mercury sphygmomanometer
ith stethoscope in the sitting position after at least 5min
est at our outpatient facility between 09:00 and 17:00.
he 13-cm width tourniquet was wrapped around the upper
rm, which was kept at the same height of the heart, and a
tethoscope was placed over the upper arm artery.
4-h ABPM
oninvasive ABPM was performed for 24 h using a FM-800®
Fukuda Denshi Ltd., Tokyo, Japan) at 30-min intervals [8].
BPM and PSG were performed on two different days. BP was
easured by the oscilloscopic method with an automated
P cuff or by the Korotkoff method. The ABPM data were
nalyzed based on the method described by Kario et al. [9]
nd the following BPs and BPd were measured: sleep BP, the
verage BP during sleep at night; awake BP, the average BP
uring the rest of the day; evening BP, the average BP 1.5 h
efore sleep; morning BP, the average BP 1.5 h immediately
fter awakening; the lowest BP, the average BP of 3 readings
entered on the lowest reading during sleep; pre-awake BP,
he average BP 1.5 h just before awakening (Fig. 1).tatistical analysis
he data are expressed as means± standard deviation. Dif-
erences between groups were determined by the analysis
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Figure 1 The time zone of blood pressure (BP). The ambulatory blood pressure monitoring (ABPM) data were analyzed based on
the method described by Kario et al. [9]: sleep BP, the average BP during sleep at night; awake BP, the average BP during the rest of
t BP,
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The day; evening BP, the average BP 1.5 h before sleep; morning
P, the average BP of 3 readings centered on the lowest readin
wakening.
f variance and the Scheffé correction was used for multi-
le comparisons. Analysis of covariance (ANCOVA) was also
sed for the evaluation of the variables. Correlations among
he groups were examined using the single regression anal-
sis. The level of statistical signiﬁcance was established at
< 0.05.
thicshis study was performed in accordance with the ethical
rinciples set forth in the Declaration of Helsinki. The study
rotocol was approved by the St. Marianna University School
f Medicine Institutional Committee on Human Research
b
t
t
t
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Table 1 Baseline characteristics.
All Non-SAS M
Number of patients 74 11 2
Sex (M/F) 63/11 6/5 1
Age (year) 45.5± 14.5 38.7± 15.3 4
Height (cm) 168.8± 7.4 165.5± 9.0 1
Weight (kg) 71.4± 12.2 62.7± 10.2 7
BMI (kg/m2) 25.0± 3.7 23.0± 3.9 2
Diabetes mellitus (%) 4 (5) 0 (0) 1
Hyperlipidemia (%) 36 (49) 2 (18) 9
Obesity (%) 6 (8) 1 (9) 1
Total cholesterol (mg/dl) 194.0± 31.8 191.0± 29.0 1
HDL cholesterol (mg/dl) 49.9± 13.6 63.0± 16.6 4
LDL cholesterol (mg/dl) 110.3± 36.5 111.3± 29.0 1
TG (mg/dl) 145.6± 96.7 83.5± 45.7 1
FPG (mg/dl) 105.6± 19.1 97.7± 11.8 1
HbA1c (%) 5.1± 0.4 4.9± 0.3 5
Creatinine (mg/dl) 0.9± 0.2 0.8± 0.2 0
SAS: sleep apnea syndrome, BMI: body mass index, HDL: high-density
fasting plasma glucose, HbA1c: glycosylated hemoglobin.
Values are presented as the mean± SD.the average BP 1.5 h immediately after awakening; the lowest
ring sleep; and pre-awake BP, the average BP 1.5 h just before
No. 1142). Written informed consent was obtained from all
f the patients prior to their enrollment.
esults
aseline characteristics
able 1 shows the baseline characteristics in each group. The
ody weight and BMI showed signiﬁcant differences among
he 4 groups (p = 0.002 and p = 0.008, respectively); whereas,
he age and height showed no signiﬁcant differences. In
he study population, 4 patients (5%) had diabetes melli-
us, 36 (49%) had hyperlipidemia, and only 6 patients (8%)
ild-SAS Moderate-SAS Severe-SAS p value
0 22 21
8/2 19/3 20/1
3.7± 14.5 49.0± 13.9 47.3± 14.4 0.23
69.3± 7.5 168.5± 6.9 170.4± 6.7 0.24
2.2± 12.2 68.9± 9.3 77.8± 13.0 0.002
5.1± 3.5 24.2± 3.0 26.7± 4.0 0.008
(5) 1 (5) 2 (10) 0.73
(45) 13 (59) 12 (57) 0.13
(5) 1 (5) 3 (14) 0.95
91.2± 25.9 200.8± 31.8 191.8± 38.1 0.75
8.6± 13.2 46.9± 11.4 47.1± 10.5 0.004
05.3± 36.9 114.7± 46.8 109.9± 28.6 0.24
58.7± 113.2 138.9± 66.5 193.1± 13.5 0.08
10.2± 15.9 105.0± 19.9 106.0± 23.3 0.40
.2± 0.5 5.1± 0.4 5.2± 0.3 0.11
.9± 0.2 0.8± 0.1 0.9± 0.1 0.52
lipoprotein, LDL: low-density lipoprotein, TG: triglyceride, FPG:
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Table 2 Sleep study data.
All Non-SAS Mild-SAS Moderate-SAS Severe-SAS p value
AHI (/h) 25.3 ± 23.2 2.0 ± 1.5 9.5 ± 2.8 22.0 ± 3.8 56.1 ± 19.8 <0.001
Arousal index (/h) 23.1 ± 20.6 8.7 ± 6.9 14.6 ± 13.5 19.9 ± 10.2 41.9 ± 25.9 <0.001
3% ODI (/h) 23.4 ± 23.9 10.3 ± 23.7 10.4 ± 4.7 18.6 ± 6.7 54.9 ± 25.8 <0.001
4% ODI (/h) 18.0 ± 22.9 7.6 ± 18.8 5.6 ± 3.2 11.9 ± 5.6 48.6 ± 27.0 <0.001
REM (%) 15.0 ± 11.0 15.1 ± 9.1 17.1 ± 5.8 17.6 ± 17.3 10.3 ± 4.6 0.12
Stage 1 (%) 23.2 ± 16.3 13.5 ± 9.7 17.2 ± 9.8 23.6 ± 10.7 33.1 ± 10.7 0.002
Stage 2 (%) 47.1 ± 12.3 45.7 ± 7.5 49.8 ± 10.3 48.6 ± 11.0 43.8 ± 16.6 0.41
Stage 3 (%) 8.3 ± 5.9 13.5 ± 9.5 9.3 ± 4.1 7.2 ± 4.8 5.7 ± 4.2 0.002
6.5
ygen
4
c
f
a
b
R
T
tStage 4 (%) 5.5 ± 6.0 8.4 ± 5.9
SAS: sleep apnea syndrome, AHI: apnea—hypopnea index, ODI: ox
Values are presented as the mean± SD.
were obese, which revealed no signiﬁcant differences. No
signiﬁcant differences in the serum concentrations of total
cholesterol, TG, LDL cholesterol, FPG, HbA1c, and creati-
nine were observed among the 4 groups. Only the serum
concentration of HDL cholesterol was higher in the non-SAS
group than the other 3 groups (p = 0.004).
Table 2 shows the sleep study data in each group. The
mean AHI increased as the severity of SAS increased. The
other variables, such as the arousal index, SpO2 90%, 3%
ODI, 4% ODI, Stage 1 and Stage 3, showed signiﬁcant differ-
ences among the 4 groups (p < 0.0001, p < 0.0001, p < 0.0001,
p < 0.0001, p = 0.002, and p = 0.002, respectively); whereas,
the REM, Stage 2 and Stage 4 showed no signiﬁcant differ-
ences.
In the present study, we investigated the association
between the sleep BP and the AHI, arousal index, 3% ODI or
a
i
h
a
p
Table 3 Blood pressure study data.
Period Blood pressure (mmHg) Non-SAS Mi
Clinic Systole 117.2 ± 12.4 12
Diastole 70.8 ± 7.2 7
24 h Systole 113.2 ± 8.4 11
Diastole 73.8 ± 5.8 7
Awake Systole 120.2 ± 12.0 12
Diastole 78.8 ± 6.9 8
Sleep Systole 103.5 ± 10.3 10
Diastole 67.1 ± 8.4 6
Evening Systole 118.8 ± 14.1 11
Diastole 78.4 ± 7.8 7
Lowest Systole 98.2 ± 10.9 10
Diastole 62.5 ± 8.6 6
Pre-awake Systole 103.4 ± 10.7 11
Diastole 66.1 ± 8.7 7
Morning Systole 120.4 ± 9.6 11
Diastole 78.3 ± 7.7 7
SAS: sleep apnea syndrome, BPs: systolic blood pressure, BPd: diastolic
Values are presented as the mean± SD.
* p < 0.05 vs. non-SAS group by analysis of variance with Scheffé corre
# p < 0.05 vs. mild-SAS group by analysis of variance with Scheffé corr
† p < 0.05 vs. moderate-SAS group by analysis of variance with Scheff± 6.2 5.0 ± 6.9 3.4 ± 4.1 0.12
desaturation index, REM: rapid eye movement.
% ODI using ANCOVA (Table 2). When the level of <5% was
onsidered statistically signiﬁcant, we found signiﬁcant dif-
erences in the arousal index (p = 0.008), 3% ODI (p = 0.027),
nd 4% ODI (p = 0.039). A signiﬁcant correlation was observed
etween the arousal index (p = 0.021) and 3% ODI (p = 0.017).
elationship between the severity of SAS and BP
able 3 shows the BPs data in each group. No differences in
he awake BPs, evening BPs, and clinic BPs were observed
mong the 4 groups. The sleep BPs was signiﬁcantly higher
n the severe-SAS group than the non-SAS group (p = 0.02);
owever, no signiﬁcant difference existed between the mild-
nd moderate- and non-SAS groups. The lowest BPs and
re-awake BPs were signiﬁcantly higher in the severe-SAS
ld-SAS Moderate-SAS Severe-SAS p value
1.8 ± 15.7 125.2 ± 9.7 128.0 ± 10.1 0.09
6.3 ± 9.4 77.0 ± 7.1 80.7 ± 8.2* 0.02
6.2 ± 8.7 121.1 ± 9.7 126.3 ± 11.4*,# 0.001
6.0 ± 6.8 78.9 ± 6.9 84.0 ± 7.4*,# <0.001
1.9 ± 9.4 126.1 ± 10.8 130.5 ± 10.9 0.27
0.6 ± 7.7 81.9 ± 9.7 85.0 ± 8.3 0.20
7.9 ± 10.3 112.8 ± 11.8† 118.7 ± 15.1* 0.005
9.1 ± 6.6 72.6 ± 8.6 79.5 ± 13.2*,# 0.002
8.7 ± 9.1 123.5 ± 11.1 126.8 ± 14.1 0.13
7.9 ± 8.2 80.3 ± 7.1 82.2 ± 8.4 0.31
0.9 ± 9.8 105.8 ± 10.8 110.0 ± 11.9* 0.01
3.3 ± 7.6 68.5 ± 9.0 69.2 ± 9.1 0.047
0.0 ± 12.8 113.4 ± 12.5 122.4 ± 16.8* 0.003
1.6 ± 8.5 73.3 ± 8.9 82.0 ± 8.5*,#,† <0.001
9.4 ± 10.4 126.2 ± 10.9 132.3 ± 13.8# 0.003
8.4 ± 8.8 81.4 ± 7.6 87.6 ± 8.5*,# 0.002
blood pressure.
ction.
ection.
é correction.
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roup (p = 0.04 and p = 0.006, respectively) than the non-
AS group. The morning BPs showed no signiﬁcant difference
etween the severe-SAS and non-SAS groups (p = 0.06); how-
ver, the severe-SAS group revealed signiﬁcantly higher
orning BPs than the mild-SAS group (p = 0.008).
Table 3 also shows the BPd data in each group. The
leep BPd was signiﬁcantly higher in the severe-SAS group
han the non-SAS and mild-SAS groups (p = 0.01 and p = 0.01,
espectively). The pre-awake BPd was signiﬁcantly higher
n the severe-SAS group than the other 3 groups (non-SAS,
= 0.0003; mild, p = 0.008; and moderate, p = 0.03). No sig-
iﬁcant differences in the awake BPd, evening BPd, and
linic BPd were observed in the severity of SAS.
In the present study, we took into account the inﬂuence
f BMI as well as AHI on sleep BP, including lowest BP and
re-awake BP, and evaluated these using ANCOVA. The sleep
Pd signiﬁcantly differed from the BMI (p = 0.003) and the
nteraction between AHI and BMI (p = 0.01), respectively.
oreover, the interaction between AHI and BMI signiﬁ-
antly differed from the pre-awake BPs (p = 0.02) and BPd
p = 0.04), respectively.
iscussion
AS is an important factor for HTN management even in
apanese patients. The prevalence of SDB is reported to be
2% in the Japanese male working population [10]. In the
resent study, no difference in the diurnal BP was observed
n the severity of SAS; however, we found higher nocturnal
P as the severity of SAS increased in the SAS patients with-
ut HTN who had normal clinic BP. The results of this study
uggested that SAS affected nocturnal BP elevation even in
AS patients without HTN.
actors affecting circadian BP changes
t baseline, signiﬁcant differences in the body weight, BMI,
nd HDL cholesterol were observed among the 4 groups. It
s considered that these factors play an important role to
nduce BP elevation.
Some studies reported that insulin resistance and
dipose-tissue speciﬁc bioactive substances, such as leptin
11] and adiponectin [12], affected BP elevation in obese
atients. In the present study, the non-SAS group had the
owest body weight and BMI, followed by the moderate-
mild-, and severe-SAS groups; however, BP in each time
one, except the morning BPs and evening BPs and BPd,
ended to be elevated as the severity of SAS increased.
ccordingly, we presumed that SAS, rather than body weight
nd BMI, affected BP elevation.
On the other hand, the non-SAS group had the highest HDL
holesterol, followed by the mild-, severe-, and moderate-
AS groups. It is well known that low HDL cholesterol is a
isk factor for arteriosclerosis and coronary artery disease
13]; however, it is still uncertain whether HDL cholesterol
lays a crucial role in circadian BP changes. Since our study
atients were normotensive, we therefore concluded that
DL cholesterol had no direct inﬂuence on the study results.
Diabetes mellitus and insulin resistance also affect cir-
adian BP changes. Some studies reported that BP rise was
n accordance with the progression of nephropathy [14,15]
n
s
r
h
pH. Sekizuka et al.
nd hyperinsulinemia due to insulin resistance [12,16]. Of
ur study population, only 4 patients (5%) had diabetes mel-
itus and the level of HbA1c was less than 6.5%; there was
o signiﬁcant difference in glycemic control among the 4
AS groups. We thus considered that diabetes mellitus and
nsulin resistance had little inﬂuence on the circadian BP
hanges because the 4 patients had early-stage diabetic
ephropathy.
In the present study, we obtained the arousal index, 3%
DI and 4% ODI and evaluated the inﬂuence of these vari-
bles on the sleep BP; however, we only found a correlation
etween the arousal index and 3% ODI. Accordingly, we con-
luded that AHI might be related to sleep BP.
he severity of SAS and the course of BP
right et al. [17] noted that SBD had no inﬂuence on the BP
easured at the clinic 5 years later in SBD patients without
TN; however, the mean 24-h BPs, the sleep BPs, and the
ighest BPs during sleep signiﬁcantly increased. Their study
esult supports our hypothesis that SAS may affect sleep
P in SAS patients without HTN. In this study, we obtained
similar result, the signiﬁcant increases in the mean 24-
BPs, sleep BPs, lowest BPs, pre-awake BPs, and morning
Ps as the severity of SAS increased. SAS was involved in BP
levation during sleep in SAS patients without HTN. Since
e found signiﬁcant differences in the body weight and BMI
mong the 4 groups, we evaluated the inﬂuence of BMI as
ell as AHI on sleep BP, lowest BP, and pre-awake BP using
NCOVA. In the SAS patients without HTN, sleep BPd became
igher as the severity of SAS increased, which was attributed
o BMI itself and the interaction between BMI and AHI. More-
ver, SAS and obesity were considered to be associated with
re-awake BP elevation. Somers et al. [18] demonstrated
hat SAS patients had high sympathetic activity when awake,
hich might trigger transitory BP surge after the resumption
f breathing due to apnea. Intermittent hypopnea due to
AS is associated with elevated sympathetic nerve activity
hich is sustained into the next morning [19]. O’Donnell et
l. [20] investigated canine models and reported that the
irway obstruction caused an increase in the mean arte-
ial pressure, which could be accentuated by prior sleep
eprivation, and that repetitive airway obstruction would
ause an increase in the mean arterial pressure over time
hat was sustained for ≥2 h when normal airway patency
as restored. They suggested that increased and persistent
ympathetic nerve activity affected BP elevation during day-
ime. Even in SAS patients with normal awake BP, SAS is
esponsible for sympathetic nerve system activation dur-
ng sleep, which results in BP changes and nocturnal HTN
8,21]. The elevated sympathetic and inhibited parasympa-
hetic nerve activities repeat every night; the frequencies
f these activities gradually increase and persist during
aytime [22]. We presumed that diurnal BP elevation contin-
ously occurred after nocturnal BP elevation in SAS patients.
oreover, BP pattern changed into non-dipper (less than 10%
octurnal BPs reduction) or riser BP (BP elevation during
leep) pattern. Cerebral, cardiac or renal disease deterio-
ates in patients with a non-dipper or riser BP pattern who
ave higher cardiovascular risks than those with dipper BP
attern [4].
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RSleep apnea syndrome and sleep blood pressure in patients
The results of this study indicated ﬁrstly the relationship
between the severity of SAS and BPd pattern; and secondly,
a similar result in BPs to our previous study which did not
investigate BPd [8]. Wright et al. [17] demonstrated that SDB
inﬂuenced a signiﬁcant increase in sleep BPd in SDB patients
without HTN. This study’s results also support the ﬁndings of
Wright et al. that SAS could affect sleep BPd in SAS patients
without HTN. To date, there is no consensus on the clinical
and prognostic meaning of BPd elevation; sleep BPd has not
been fully evaluated. We believe that intervention treat-
ment for BPd as well as BPs possibly prevents the onset of
cardiovascular diseases.
Recently, the importance of nocturnal BP changes has
been recognized. The normal nocturnal decrease in BP aver-
ages 10—20% below daytime levels [3,23], because inhibited
sympathetic nerve activity reduces BP during sleep [24]. In
contrast, many SAS patients have non-dipper BP or riser BP
pattern because they have an attenuated or absent fall in
nocturnal BP. Therefore, nocturnal BP change is more use-
ful to predict cardiovascular events than BP measured at
clinic or home and awake BP [25]. We consider that SAS
contributes to the occurrence of nocturnal HTN. Obstruc-
tive SAS (OSAS) patients have a signiﬁcantly increased risk
of sudden death from cardiac causes during sleep and a
marked nocturnal peak in sudden death [26]. Ohkubo et al.
[23] reported that the mortality risk was highest in inverted
dippers, followed by non-dippers. Many OSAS patients have
non-dipper or riser BP pattern and show BP surge in the
early morning [27]. Accordingly, appropriate treatment for
SAS patients without HTN may well prevent not only noc-
turnal and morning BP elevation but also future HTN and
cardiovascular events. One study has suggested that SAS in
patients without HTN affects sleep that occupies one-third
of the human life span, which will lead to dysautonomia,
increased renin—angiotensin—aldosterone system activity,
BP changes, and nocturnal BP elevation [28]. It is also
reported that arterial stiffness, which is evaluated by the
pulse wave velocity and left ventricular function, signif-
icantly increases as the severity of SAS increases [29];
however, these mechanisms have not been fully elucidated.
SAS may therefore be associated with future HTN and
nocturnal BP elevation which triggers organ disorders and
cardiovascular events.
Study limitations
Since many SAS patients had high BP, it was quite difﬁ-
cult to ﬁnd SAS patients with normal BP, especially non-SAS
patients with normal BP. A further study with a larger pop-
ulation should be required. The adequacy of BP measured
at the clinic, which identiﬁed the patients with or with-
out HTN, was valid because all patients had the mean
awake BPs < 140mmHg and BPd < 90mmHg. Since there is
no consensus on the deﬁnition of nocturnal BP elevation
and abnormal BP reduction during sleep based on ABPM, it
is still a matter of debate which is more clinically impor-
tant, sleep BP or abnormal BP reduction during sleep. It is
vital to conduct a further study to accumulate data. In HTN
patients, nocturnal BP elevation, such as non-dipper BP, is
considered as a trigger of cardiovascular events; however, no
study has yet investigated whether nocturnal BP elevationout hypertension 97
s associated with the onset of cardiovascular events and BP
levation during daytime. Further investigations regarding
hese points are thus called for.
onclusions
his study demonstrated the relationship between the
everity of SAS and circadian BP changes using PSG and
BPM, which suggested that SAS affected nocturnal BP ele-
ation even in SAS patients without HTN. In the present
tudy, we found no difference in the diurnal BP in the
everity of SAS; however, the nocturnal BP was signiﬁcantly
levated in the severe-SAS group.
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